AstraZeneca Pharma India (ASTRAZEN) Stock Overview
A biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
ASTRAZEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AstraZeneca Pharma India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹9,033.50 |
| 52 Week High | ₹10,691.00 |
| 52 Week Low | ₹6,312.75 |
| Beta | 0.18 |
| 1 Month Change | -0.48% |
| 3 Month Change | 0.42% |
| 1 Year Change | 36.27% |
| 3 Year Change | 165.13% |
| 5 Year Change | 103.69% |
| Change since IPO | 1,380.90% |
Recent News & Updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S Still Appears To Be Reasonable
Oct 01
Should You Be Adding AstraZeneca Pharma India (NSE:ASTRAZEN) To Your Watchlist Today?
Sep 06We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Can Stay On Top Of Its Debt
Aug 16Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S Still Appears To Be Reasonable
Oct 01Should You Be Adding AstraZeneca Pharma India (NSE:ASTRAZEN) To Your Watchlist Today?
Sep 06We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Can Stay On Top Of Its Debt
Aug 16AstraZeneca Pharma India (NSE:ASTRAZEN) Is Increasing Its Dividend To ₹32.00
Jul 16AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S Is Still On The Mark Following 26% Share Price Bounce
Jun 10AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) 28% Jump Shows Its Popularity With Investors
Mar 31AstraZeneca Pharma India (NSE:ASTRAZEN) Seems To Use Debt Quite Sensibly
Mar 12Investors Appear Satisfied With AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Prospects
Dec 31AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28Shareholder Returns
| ASTRAZEN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.2% | -1.3% | -1.7% |
| 1Y | 36.3% | -3.8% | -3.3% |
Return vs Industry: ASTRAZEN exceeded the Indian Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: ASTRAZEN exceeded the Indian Market which returned -3.5% over the past year.
Price Volatility
| ASTRAZEN volatility | |
|---|---|
| ASTRAZEN Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.0% |
Stable Share Price: ASTRAZEN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ASTRAZEN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 600 | Praveen Akkinepally | www.astrazeneca.in |
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services.
AstraZeneca Pharma India Limited Fundamentals Summary
| ASTRAZEN fundamental statistics | |
|---|---|
| Market cap | ₹225.66b |
| Earnings (TTM) | ₹1.99b |
| Revenue (TTM) | ₹20.06b |
Is ASTRAZEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASTRAZEN income statement (TTM) | |
|---|---|
| Revenue | ₹20.06b |
| Cost of Revenue | ₹11.32b |
| Gross Profit | ₹8.74b |
| Other Expenses | ₹6.75b |
| Earnings | ₹1.99b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 14, 2026
| Earnings per share (EPS) | 79.66 |
| Gross Margin | 43.56% |
| Net Profit Margin | 9.93% |
| Debt/Equity Ratio | 0% |
How did ASTRAZEN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/09 06:36 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca Pharma India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |